Opinion on Pharmaceuticals

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

"The pill" goes natural with potential new bestseller

Teva has announced the EU approval of NOMAC/E2, the first monophasic contraceptive with natural estrogen. The perceived increased safety of natural estrogen and a global launch will drive sales of the product, making it a leading hormonal contraceptive brand. To maximize its potential, however, Teva needs to show improved safety over synthetic estrogen contraceptives in post-marketing studies.

Published By Datamonitor
03 Aug 2011
Expert View
Expert View

A blockbuster is born in Johnson & Johnson's Nucynta ER

Johnson & Johnson has received FDA approval for Nucynta ER in moderate to severe chronic pain. Backed by clinical trial data showing comparable efficacy and superior tolerability to the market-leading opioid, OxyContin, Nucynta ER will be a commercial success for Johnson & Johnson. Additional benefits in neuropathic pain will further strengthen the clinical argument for its use.

Published By Datamonitor
30 Aug 2011
Expert View
Expert View

A changing European pharmaceuticals market

The European pharmaceuticals market is set for significant change this year. The accession of an additional ten member states into the EU is likely to affect the market as a whole with a particular impact on regulations, pricing, and parallel trade. These factors added to a growing generics field should present industry access to relatively untapped markets with long-term revenue potential.

Published By Datamonitor
16 Jan 2004
Expert View
Expert View

AAN 2010: late-stage pipeline candidates take center stage in migraine

In the wake of Imitrex's and Topamax's patent expiries, announcements at this year's American Academy of Neurology meeting focused firmly on the next major breakthroughs for the acute and prophylactic migraine markets. Pooled data for candidates from Allergan and Merck & Co demonstrated impressive potential, suggesting renewed hope for sufferers.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: new treatments address unmet needs in Alzheimer's and epilepsy

A number of leading drug makers used this year's meeting of the American Academy of Neurology to present new data for promising pipeline candidates. Despite promising results, however, Datamonitor believes that the epilepsy drugs will struggle to find their place in the market. Moreover, the positive Phase II data for Baxter's potential Alzheimer's therapy Gammagard do not guarantee later success.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: spotlight shines on Novartis' and Merck KGaA's oral MS candidates

Datamonitor attended this year's American Academy of Neurology conference, where developments in multiple sclerosis took precedence for the third consecutive year. Both Novartis and Merck KGaA presented new data for their pipeline candidates, while Acorda used the meeting as a platform to share data for its symptomatic treatment Ampyra, which was recently approved by the FDA.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2011: Gilenya raises the bar for prospective MS market entrants

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. For another year running, developments in multiple sclerosis (MS) treatment research dominated proceedings. Below are the highlights of the conference's coverage of new multiple sclerosis drugs.

Published By Datamonitor
03 May 2011
Expert View
Expert View

AAN 2011: key themes in the migraine field include rapid-acting drugs and Botox

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. Below are the highlights of the conference's coverage of new migraine drugs.

Published By Datamonitor
03 May 2011
Expert View
Expert View

AAN 2011: new anti-epileptics with novel mechanisms take center stage

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. Developments in late-stage pipeline agents for epilepsy were a key talking point at AAN 2011. Below are the highlights of the conference's coverage of new anti-epileptic drugs.

Published By Datamonitor
03 May 2011
Expert View
Expert View

AAN 2011: promising new Parkinson's treatment options may reduce motor fluctuations

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. Developments in late-stage pipeline agents for Parkinson's disease were a key talking point at AAN 2011. Below are the highlights of the conference's coverage of new Parkinson's drugs.

Published By Datamonitor
03 May 2011

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.